Description: The PowerShares Dynamic Biotechnology & Genome Portfolio seeks investment results that correspond generally to the price and yield (before the Fund's fees and expenses) of an equity index called the Dynamic Biotechnology & Genome Intellidex Index (the "Underlying Intellidex"). The Underlying Intellidex is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include, for example, companies involved in the research, development or production of pharmaceuticals, including veterinary drugs. Stocks are selected principally on the basis of their capital appreciation potential as identified by NYSE Arca pursuant to a proprietary Intellidex methodology. The Fund will normally invest at least 80% of its total assets in common stocks of biotechnology companies and genome companies.
|BIIB||Biogen Idec Inc||5.54%|
|LIFE||Life Technologies Corp.||4.89%|
|INSY||Insys Therapeutics Inc.||3.76%|
Data is provided by Zacks Investment Research